$NMTC From a recent 424B5: "NeuroOne Medical Technologies Corporation filed a prospectus supplement (424B5) on June 12, 2026, to amend its existing registration statement. This filing supplements prior prospectuses related to at" — momentum can ignore this for a week; the cap table can't. We map filings like this ticker-by-ticker on SmallCapDilution. #SEC #microcap #NMTC

$NMTC NeuroOne Medical Technologies Corporation ATM Offering Increase (Jun 12, 2026) Filings today reference an increase in the aggregate amount of common stock eligible for sale under an ATM offering: • Aggregate amount of common stock eligible for sale increased to $13,400,000. • Approximately $8,359,586 of common stock had been sold as of the filing date. • Last reported sale price of NMTC common stock was $3.24 per share on June 11, 2026. NeuroOne Medical Technologies Corporation filed a prospectus supplement to amend its existing registration statement, supplementing prior prospectuses related to at-the-market (ATM) offerings of common stock conducted through a Sales Agreement with JonesTrading Institutional Services LLC. Check our RESEARCH tab for a free report on NMTC and its activity. Hours of research saved. This filing relates to the ongoing management of the company's capital structure through at-the-market equity offerings. #MicroCap #DilutionWatch #NMTC

NeuroOne to Present Commercialization Updates at Planet MicroCap Las Vegas Conference | MEXC News mexc.com/news/1134273

NeuroOne to Present Commercialization Updates at Planet MicroCap Las Vegas Conference - citybuzz citybuzz.co/2026/06/08/neuro…

@N1MTC is proud to highlight the scientific and clinical posters related to the OneRF® Ablation System and other NeuroOne products in development. These will be presented at the American Association of Neurological Surgeons (AANS) 2026 Annual Meeting. (Caution: RxOnly)

NeuroOne Medical Technologies Corporation CEO Dave Rosa Featured on Xtalks Life Science Podcast Watch the Interview Here: ow.ly/b9ZK50YQHf8 $NMTC #NeuroOne #OneRF® @N1MTC ir.nmtc1.com

Epilepsy treatment that delivers anti-seizure medication directly to the brain. This innovative collaboration w/ Dr. Sandip Pati & NeuroOne aims to improve precision, reduce side effects & bring new hope to patients with drug-resistant epilepsy. Read more: mndrivebrainconditions.umn.e…

🪙 US Penny Stocks Below $1 — Top Gainers | Mar 3, 2026 $MOBX | Mobix Labs: $0.68 ( 282.09%) $SVRN | OceanPal: $0.68 ( 56.64%) $CCHH | CCH Ltd: $0.68 ( 50.76%) $EONR | EON Resources: $0.67 ( 35.24%) $ONCO | Onconetix: $0.87 ( 33.74%) $BRCC | BRC: $0.78 ( 21.38%) $CALC | CalciMedica: $0.61 ( 20.32%) $NMTC | NeuroOne Medical Technologies: $0.77 ( 15.53%) $HIHO | Highway Limited: $0.93 ( 9.74%) $PRSO | Peraso: $0.92 ( 7.63%) $FBLG | FibroBiologics: $0.44 ( 5.24%) $PED | Pedevco: $0.72 ( 3.11%) $SHFS | SHF: $0.83 ( 1.23%) $ADV | Advantage Solutions: $0.55 ( 0.45%) $PPCB | Propanc Biopharma: $0.18 (-0.60%) #daytrading

🚨Insider Trade Alert🚨! Chief Business Officer Wambeke David J. has purchased 1,000,000 shares of $NMTC (NEUROONE MEDICAL TECHNOLOGIES Corp) at $0.67 worth $670,400.00 $NMTC current value: $0.67 full disclosure: sec.gov/Archives/edgar/data/… Company Overview: NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company is based in Eden Prairie, Minnesota.

Jones Trading Starts Neuroone Medical Technologies at Buy invst.ly/1ftnid

NeuroOne® to Host Virtual Investor Webinar on Thursday, March 12, 2026 at 11:30 AM ET ow.ly/zTV050YmpvQ Dial-In: 888-506-0062 Int'l: 973-528-0011 Access Code: 358063 Webcast: ow.ly/r2et50YmpvS $NMTC #NeuroOne #OneRF® @N1MTC ir.nmtc1.com

Today at 1:30 PM EST, the CEO of $NMTC will be joining us on X Spaces for a live conversation. 🎙️ Inside NeuroOne Medical Technologies A live discussion with CEO Dave Rosa. x.com/i/spaces/1eaKbjanrEVKX…

Tune in on Monday at 1:30PM EST on Spaces! Topic: Inside NeuroOne Medical Technologies | CEO Dave Rosa HOST: @WOLF_Financial Co-Hosts: @StoryTrading_IR @StoryTrading Speakers: @DROSA50 @DougieFreshPick @MoneyMarkStocks @laptoptravel

“There were devices that could do diagnostics, and others that could only do therapeutics, but none that could do both.” — Dave Rosa, CEO, NeuroOne Medical Technologies Takeaway: Owning more of the procedure matters more than selling more devices. Integrated platforms create switching costs, and that’s where long-term MedTech value compounds. Watching $NMTC closely.

Neiry-Next-Generation Thin-Film Electrodes Thinner Than a Human Hair Key takeaways The Neiry Group is adopting and securing intellectual property rights for innovative ultra-thin film electrodes developed by one of their technological/scientific partners. These electrodes represent a major step forward in neurointerfaces and biomedical tech in Russia. Extreme thinness → Only 15 micrometers thick (several times thinner than a human hair, which is typically ~50–100 μm), making them minimally invasive and highly flexible. Built-in microchips in each electrode → These handle local signal amplification and digitization right at the source. This allows part of the electronics to be placed directly near the neural activity (inside the body), significantly improving signal quality and reducing noise compared to traditional setups. Bidirectional capability → The technology supports a full bidirectional brain-computer interface, meaning it can both: Read neural signals from nerve cells. Send stimulating impulses back to the brain/organism. This enables true two-way communication between a computer and living tissue. Advantages Over Existing Solutions: Much lower production costs — Described as "dozens of times cheaper" than conventional alternatives, thanks to a patented thin-film processing technology. Biocompatibility — Made from modern, medically approved materials commonly used in microelectronics. Edge over Western analogues — The article specifically notes a significant advantage over products like those from NeuroOne due to the integrated on-electrode microchip processing. neiry.ru/en/news/bhp5xxeg21-…

Tune in at 1:30 PM ET as we interview the CEO of NeuroOne Medical Technologies Corp, ticker $NMTC 👇 youtube.com/live/W9YtHWqUC6w

NeuroOne Medical Technologies (@N1MTC) dropped a monster Q4 Quick hits (via @YahooFinance): • Product revenue up 907% in Q4 • FY revenue climbed to $9.1M ( 163%) • Gross margins expanded to 56% • Operating costs declined • Balance sheet strengthened, no debt Execution is showing up in the numbers. More coverage coming. Link in comments to the full article.

Tune in tonight at 7PM EST for a deep dive into NeuroOne Medical Technologies with CEO Dave Rosa $NMTC @N1MTC x.com/i/broadcasts/1MYGNlmNz…

Gatewatch is starting coverage on NeuroOne Medical Technologies, @N1MTC. Micro-cap medtech. Multi-market platform. Three fast facts: • Multi-billion dollar market • Gross margins 50% • Partnerships with @MayoClinic @zimmerbiomet We’ll be tracking how this story develops. More coming soon.

Please join us for AMA 100 with Dave Rosa, CEO of NeuroOne Medical Technologies, on January 12 2026 at 7 pm Eastern, 6 pm Central, and 4 pm Pacific. x.com/i/broadcasts/1nAJEEAZv…